Axsome Therapeutics, Inc.: Depressive Disorder, Major trials
The registry lists 10 Depressive Disorder, Major studies with Axsome Therapeutics, Inc. as lead sponsor. 2 are open to participants now and 4 have results posted.
Phase 2 4Phase 3 5Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolRecruitingNCT07484217Phase 3
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsRecruitingNCT06223880Phase 4
- Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)TerminatedNCT04634669Phase 2Results posted
- Open-Label Safety Study of AXS-05 in Subjects With DepressionCompletedNCT04039022Phase 3Results posted
- A Trial of AXS-05 in Patients With Major Depressive DisorderCompletedNCT04019704Phase 3Results posted
- Assessing Symptomatic Clinical Episodes in DepressionCompletedNCT03595579Phase 2Results posted
- Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolCompletedNCT06360419Phase 3
- An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent PatientsStatus unknownNCT04971291Phase 2
- Mechanistic Evaluation of Response in TRD (MERIT)CompletedNCT04608396Phase 2
- A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderCompletedNCT02741791Phase 3